Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine.

Human induced pluripotent stem cells (hiPSCs) have revolutionized the field of human disease modeling, with an enormous potential to serve as paradigm shifting platforms for preclinical trials, personalized clinical diagnosis, and drug treatment. In this review, we describe how hiPSCs could transition cardiac healthcare away from simple disease diagnosis to prediction and prevention, bridging the gap between basic and clinical research to bring the best science to every patient.

[1]  U. Landmesser,et al.  Restrictive cardiomyopathy , 2017, Wiener klinische Wochenschrift.

[2]  Divya Rajamohan,et al.  Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform☆ , 2016, Biochimica et biophysica acta.

[3]  I. Y. Chen,et al.  Induced pluripotent stem cells: at the heart of cardiovascular precision medicine , 2016, Nature Reviews Cardiology.

[4]  Russ B Altman,et al.  Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity , 2016, Nature Medicine.

[5]  Nazish Sayed,et al.  Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine. , 2016, Journal of the American College of Cardiology.

[6]  Tanuj Kanchan,et al.  Human Genome Editing and Ethical Considerations , 2015, Science and Engineering Ethics.

[7]  W. Riley,et al.  Precision Public Health for the Era of Precision Medicine. , 2016, American journal of preventive medicine.

[8]  Md. Abul Hassan Samee,et al.  Complex Interdependence Regulates Heterotypic Transcription Factor Distribution and Coordinates Cardiogenesis , 2016, Cell.

[9]  J. Vockley,et al.  Precision medicine in the age of big data: The present and future role of large‐scale unbiased sequencing in drug discovery and development , 2016, Clinical pharmacology and therapeutics.

[10]  E. Schulze-Bahr,et al.  Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction , 2016, Basic Research in Cardiology.

[11]  C. Siu,et al.  Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA. , 2016, International journal of cardiology.

[12]  Praveen Shukla,et al.  Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies. , 2016, Advanced drug delivery reviews.

[13]  Timothy J. Nelson,et al.  Modeling structural and functional deficiencies of RBM20 familial dilated cardiomyopathy using human induced pluripotent stem cells. , 2016, Human molecular genetics.

[14]  J. Pritchard,et al.  Genetic Variation, Not Cell Type of Origin, Underlies the Majority of Identifiable Regulatory Differences in iPSCs , 2016, PLoS genetics.

[15]  P. Burridge,et al.  Modeling Cardiovascular Diseases with Patient-Specific Human Pluripotent Stem Cell-Derived Cardiomyocytes. , 2016, Methods in molecular biology.

[16]  S. Yamanaka,et al.  From Genomics to Gene Therapy: Induced Pluripotent Stem Cells Meet Genome Editing. , 2015, Annual review of genetics.

[17]  P. Burridge,et al.  Genetic and Epigenetic Regulation of Human Cardiac Reprogramming and Differentiation in Regenerative Medicine. , 2015, Annual review of genetics.

[18]  Behnam Ebrahimi,et al.  Reprogramming barriers and enhancers: strategies to enhance the efficiency and kinetics of induced pluripotency , 2015, Cell Regeneration.

[19]  M. Alexander,et al.  Scaling human pluripotent stem cell expansion and differentiation: are cell factories becoming a reality? , 2015, Regenerative medicine.

[20]  F. Sasarman,et al.  Mitochondrial Diseases and Cardiomyopathies. , 2015, The Canadian journal of cardiology.

[21]  A. Mani,et al.  The Genetic Challenges and Opportunities in Advanced Heart Failure. , 2015, The Canadian journal of cardiology.

[22]  J. Rinn,et al.  A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs , 2015, Nature Biotechnology.

[23]  Gregory F. Lewis,et al.  High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays. , 2015, Toxicology and applied pharmacology.

[24]  S. Haupt,et al.  A reproducible and versatile system for the dynamic expansion of human pluripotent stem cells in suspension. , 2015, Biotechnology journal.

[25]  P. Burridge,et al.  Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells , 2015, Current protocols in human genetics.

[26]  T. Cathomen,et al.  Proven and novel strategies for efficient editing of the human genome. , 2015, Current opinion in pharmacology.

[27]  Kin-Fan Au,et al.  PacBio Sequencing and Its Applications , 2015, Genom. Proteom. Bioinform..

[28]  Don Paul Kovarcik,et al.  cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications , 2015, Stem cell reports.

[29]  M. Gollob,et al.  Genetics of inherited primary arrhythmia disorders , 2015, The application of clinical genetics.

[30]  C. Pc,et al.  The human subject: an integrative animal model for 21(st) century heart failure research. , 2015 .

[31]  P. Shen,et al.  A Rapid, High-Quality, Cost-Effective, Comprehensive and Expandable Targeted Next-Generation Sequencing Assay for Inherited Heart Diseases. , 2015, Circulation research.

[32]  E. Amsterdam,et al.  The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease , 2015, Clinical cardiology.

[33]  G. Stacey,et al.  Impact of National and International Stem Cell Banking Initiatives on progress in the field of cell therapy: IABS-JST Joint Workshop: Summary for Session 5. , 2015, Biologicals : journal of the International Association of Biological Standardization.

[34]  Praveen Shukla,et al.  Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells. , 2015, Stem cell research.

[35]  Alexander Meissner,et al.  Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells , 2015, Nature Methods.

[36]  F. Charpentier,et al.  Toward Personalized Medicine: Using Cardiomyocytes Differentiated From Urine-Derived Pluripotent Stem Cells to Recapitulate Electrophysiological Characteristics of Type 2 Long QT Syndrome , 2015, Journal of the American Heart Association.

[37]  George Church,et al.  Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy , 2015, Science.

[38]  Daniel Spies,et al.  Dynamics in Transcriptomics: Advancements in RNA-seq Time Course and Downstream Analysis , 2015, Computational and structural biotechnology journal.

[39]  Y. Eto,et al.  Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient , 2015, Molecular therapy. Methods & clinical development.

[40]  Michael Eldar,et al.  Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations , 2015, Journal of cellular and molecular medicine.

[41]  Donald M Bers,et al.  Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy. , 2015, Cell stem cell.

[42]  Xiaofang Sun,et al.  Effects of Integrating and Non-Integrating Reprogramming Methods on Copy Number Variation and Genomic Stability of Human Induced Pluripotent Stem Cells , 2015, PloS one.

[43]  I. Karakikes,et al.  Induced Pluripotent Stem Cell–Derived Cardiomyocytes: A New and Versatile Human In Vitro Cardiomyocyte Model Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Insights Into Molecular, Cellular, and Functional Phenotypes , 2015 .

[44]  B. Malgrange,et al.  Generation of Isogenic Human iPS Cell Line Precisely Corrected by Genome Editing Using the CRISPR/Cas9 System , 2015, Stem Cell Reviews and Reports.

[45]  Philip T Sager,et al.  Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. , 2015, Circulation research.

[46]  M. Snyder,et al.  High-throughput sequencing technologies. , 2015, Molecular cell.

[47]  Jacqueline Corrigan-Curay,et al.  Genome Editing Technologies: Defining a Path to Clinic: Genomic Editing: Establishing Preclinical Toxicology Standards, Bethesda, Maryland 10 June 2014. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  S. Barlas Precision medicine initiative aims for a new generation of diagnostics and treatments: but is the promise of genetic targeting overinflated? , 2015, P & T : a peer-reviewed journal for formulary management.

[49]  G. Bett,et al.  Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy , 2015, Disease Models & Mechanisms.

[50]  Ronald A. Li,et al.  Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy , 2015, Nature Communications.

[51]  Y. Pinto,et al.  Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. , 2015, Cardiovascular research.

[52]  Darren R. Williams,et al.  Making cardiomyocytes with your chemistry set: Small molecule-induced cardiogenesis in somatic cells. , 2015, World journal of cardiology.

[53]  Stuart A Cook,et al.  Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes , 2015, Stem Cell Research & Therapy.

[54]  Bruce R. Conklin,et al.  A Non-invasive Platform for Functional Characterization of Stem-Cell-Derived Cardiomyocytes with Applications in Cardiotoxicity Testing , 2015, Stem cell reports.

[55]  Eli R. Zunder,et al.  A continuous molecular roadmap to iPSC reprogramming through progression analysis of single-cell mass cytometry. , 2015, Cell stem cell.

[56]  Arthur S Slutsky,et al.  Preclinical target validation using patient-derived cells , 2015, Nature Reviews Drug Discovery.

[57]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[58]  Moritoshi Sato,et al.  CRISPR-Cas9-based photoactivatable transcription system. , 2015, Chemistry & biology.

[59]  Robert Passier,et al.  Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology , 2015, EMBO molecular medicine.

[60]  Marius Wernig,et al.  Early reprogramming regulators identified by prospective isolation and mass cytometry , 2015, Nature.

[61]  A. Lindahl,et al.  Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells , 2015, Toxicology.

[62]  Alexandro E. Trevino,et al.  Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex , 2014, Nature.

[63]  M. Kay,et al.  Novel codon-optimized mini-intronic plasmid for efficient, inexpensive, and xeno-free induction of pluripotency , 2015, Scientific Reports.

[64]  Mark D. Huffman,et al.  AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .

[65]  Y. Usson,et al.  Modular organization of cardiac energy metabolism: energy conversion, transfer and feedback regulation , 2015, Acta physiologica.

[66]  J. Pippin,et al.  The human subject: an integrative animal model for 21(st) century heart failure research. , 2015, American journal of translational research.

[67]  James A Thomson,et al.  Pompe Disease Results in a Golgi-based Glycosylation Deficit in Human Induced Pluripotent Stem Cell-derived Cardiomyocytes* , 2014, The Journal of Biological Chemistry.

[68]  D. Malan,et al.  Robust Generation of Cardiomyocytes from Human iPS Cells Requires Precise Modulation of BMP and WNT Signaling , 2014, Stem Cell Reviews and Reports.

[69]  K. Node,et al.  Endothelin‐1 Induces Myofibrillar Disarray and Contractile Vector Variability in Hypertrophic Cardiomyopathy–Induced Pluripotent Stem Cell–Derived Cardiomyocytes , 2014, Journal of the American Heart Association.

[70]  K. Kolaja,et al.  Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. , 2014, Cell reports.

[71]  N. Risch,et al.  Estimating genotype error rates from high-coverage next-generation sequence data , 2014, Genome research.

[72]  Robert Zweigerdt,et al.  Controlling Expansion and Cardiomyogenic Differentiation of Human Pluripotent Stem Cells in Scalable Suspension Culture , 2014, Stem cell reports.

[73]  D. Arnett,et al.  RNA Expression Profiling of Human iPSC-Derived Cardiomyocytes in a Cardiac Hypertrophy Model , 2014, PloS one.

[74]  P. Burridge,et al.  Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system , 2014, Science Translational Medicine.

[75]  Lei Yang,et al.  Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells , 2014, Cardiovascular research.

[76]  Roger A. Pedersen,et al.  NANOG and CDX2 pattern distinct subtypes of human mesoderm during exit from pluripotency. , 2014, Cell stem cell.

[77]  A. Clarke Managing the ethical challenges of next-generation sequencing in genomic medicine. , 2014, British medical bulletin.

[78]  C. Thermes,et al.  Ten years of next-generation sequencing technology. , 2014, Trends in genetics : TIG.

[79]  Benjamin D. Simons,et al.  Early lineage restriction in temporally distinct populations of Mesp1 progenitors during mammalian heart development , 2014, Nature Cell Biology.

[80]  Dietrich Rebholz-Schuhmann,et al.  Biological network extraction from scientific literature: state of the art and challenges , 2014, Briefings Bioinform..

[81]  K. Red-Horse,et al.  Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes as an In Vitro Model for Coxsackievirus B3–Induced Myocarditis and Antiviral Drug Screening Platform , 2014, Circulation research.

[82]  O. Abilez,et al.  Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells. , 2014, Journal of the American College of Cardiology.

[83]  M. Kay,et al.  Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. , 2014, Journal of the American College of Cardiology.

[84]  Praveen Shukla,et al.  Chemically defined generation of human cardiomyocytes , 2014, Nature Methods.

[85]  C. Gersbach,et al.  Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine , 2014, Expert opinion on therapeutic targets.

[86]  G. Fishman,et al.  Identification and Purification of Human Induced Pluripotent Stem Cell-Derived Atrial-Like Cardiomyocytes Based on Sarcolipin Expression , 2014, PloS one.

[87]  Kun Zhang,et al.  Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. , 2014, Cell stem cell.

[88]  Feng Chen,et al.  Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. , 2014, Cell stem cell.

[89]  Chad A. Cowan,et al.  Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. , 2014, Cell stem cell.

[90]  C. Abi Khalil The emerging role of epigenetics in cardiovascular disease , 2014, Therapeutic advances in chronic disease.

[91]  E. Knapik,et al.  Gremlin 2 Promotes Differentiation of Embryonic Stem Cells to Atrial Fate by Activation of the JNK Signaling Pathway , 2014, Stem cells.

[92]  George M. Church,et al.  CRISPR/Cas9‐Directed Genome Editing of Cultured Cells , 2014, Current protocols in molecular biology.

[93]  Ulf Leser,et al.  Trends in Genome Compression , 2014 .

[94]  M. Yacoub,et al.  The role of endothelin-1 in pulmonary arterial hypertension , 2014, Global cardiology science & practice.

[95]  Paul W. Burridge,et al.  Human Stem Cells for Modeling Heart Disease and for Drug Discovery , 2014, Science Translational Medicine.

[96]  D. Zheng,et al.  DNA Methylation is Developmentally Regulated for Genes Essential for Cardiogenesis , 2014, Journal of the American Heart Association.

[97]  Daniel J. Gaffney,et al.  Genetic Background Drives Transcriptional Variation in Human Induced Pluripotent Stem Cells , 2014, PLoS genetics.

[98]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[99]  Y. Higaki,et al.  Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency. , 2014, Biochemical and biophysical research communications.

[100]  Gang Wang,et al.  Modeling the mitochondrial cardiomyopathy of Barth syndrome with iPSC and heart-on-chip technologies , 2014 .

[101]  Jose M Polo,et al.  Phases of reprogramming. , 2014, Stem cell research.

[102]  Martin J. Aryee,et al.  Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing , 2014, Nature Biotechnology.

[103]  V. Iyer,et al.  Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects , 2014, Nature Methods.

[104]  David A. Scott,et al.  Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells , 2014, Nature Biotechnology.

[105]  Desheng Liang,et al.  TALE nickase mediates high efficient targeted transgene integration at the human multi-copy ribosomal DNA locus. , 2014, Biochemical and biophysical research communications.

[106]  E. Sernagor,et al.  An Induced Pluripotent Stem Cell Model of Hypoplastic Left Heart Syndrome (HLHS) Reveals Multiple Expression and Functional Differences in HLHS‐Derived Cardiac Myocytes , 2014, Stem cells translational medicine.

[107]  Ronald A. Li,et al.  A simple, cost-effective but highly efficient system for deriving ventricular cardiomyocytes from human pluripotent stem cells. , 2014, Stem cells and development.

[108]  J. Keith Joung,et al.  Broad Specificity Profiling of TALENs Results in Engineered Nucleases With Improved DNA Cleavage Specificity , 2014, Nature Methods.

[109]  Lil Pabon,et al.  Engineering Adolescence: Maturation of Human Pluripotent Stem Cell–Derived Cardiomyocytes , 2014, Circulation research.

[110]  Ravi Iyengar,et al.  Small Molecule‐Mediated Directed Differentiation of Human Embryonic Stem Cells Toward Ventricular Cardiomyocytes , 2014, Stem cells translational medicine.

[111]  K. Morgan,et al.  Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes , 2013, European heart journal.

[112]  Joseph C. Wu,et al.  Second generation codon optimized minicircle (CoMiC) for nonviral reprogramming of human adult fibroblasts. , 2014, Methods in molecular biology.

[113]  David R. Liu,et al.  Determining the specificities of TALENs, Cas9, and other genome-editing enzymes. , 2014, Methods in enzymology.

[114]  Azra Fatima,et al.  The Disease-Specific Phenotype in Cardiomyocytes Derived from Induced Pluripotent Stem Cells of Two Long QT Syndrome Type 3 Patients , 2013, PloS one.

[115]  L. Gepstein,et al.  Modeling of Arrhythmogenic Right Ventricular Cardiomyopathy With Human Induced Pluripotent Stem Cells , 2013, Circulation. Cardiovascular genetics.

[116]  Jiangnan Yu,et al.  Non‐Viral Co‐Delivery of the Four Yamanaka Factors for Generation of Human Induced Pluripotent Stem Cells via Calcium Phosphate Nanocomposite Particles , 2013 .

[117]  Joseph C. Wu,et al.  Patient-specific stem cells and cardiovascular drug discovery. , 2013, JAMA.

[118]  Kumaraswamy Nanthakumar,et al.  Design and formulation of functional pluripotent stem cell-derived cardiac microtissues , 2013, Proceedings of the National Academy of Sciences.

[119]  Simona Casini,et al.  Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome , 2013, The EMBO journal.

[120]  Luke A. Gilbert,et al.  CRISPR interference (CRISPRi) for sequence-specific control of gene expression , 2013, Nature Protocols.

[121]  Teng Hong Tan,et al.  Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. , 2013, International journal of cardiology.

[122]  Zohar Mukamel,et al.  Deterministic direct reprogramming of somatic cells to pluripotency , 2013, Nature.

[123]  M Miragoli,et al.  CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia , 2013, Cell Death and Disease.

[124]  Natsuyo Aoyama,et al.  Phenotypic Screening with Human iPS Cell–Derived Cardiomyocytes , 2013, Journal of biomolecular screening.

[125]  Donald M Bers,et al.  Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays , 2013, Circulation.

[126]  P. Shannon,et al.  Fetal reprogramming and senescence in hypoplastic left heart syndrome and in human pluripotent stem cells during cardiac differentiation. , 2013, The American journal of pathology.

[127]  Waqar Hussain,et al.  Reproducible culture and differentiation of mouse embryonic stem cells using an automated microwell platform☆ , 2013, Biochemical engineering journal.

[128]  H. Deng,et al.  Pluripotent Stem Cells Induced from Mouse Somatic Cells by Small-Molecule Compounds , 2013, Science.

[129]  M. Hayden,et al.  Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline‐induced cardiotoxicity in children , 2013, Pediatric blood & cancer.

[130]  M. Morad,et al.  Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. , 2013, Cell calcium.

[131]  R. Jaenisch,et al.  One-Step Generation of Mice Carrying Reporter and Conditional Alleles by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.

[132]  A. Muotri,et al.  Efficient generation of human iPSCs by a synthetic self-replicative RNA. , 2013, Cell stem cell.

[133]  C. Mummery,et al.  Generation of induced pluripotent stem cells from human foetal fibroblasts using the Sleeping Beauty transposon gene delivery system. , 2013, Differentiation; research in biological diversity.

[134]  C. Barbas,et al.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.

[135]  Kumaraswamy Nanthakumar,et al.  Biowire: a New Platform for Maturation of Human Pluripotent Stem Cell Derived Cardiomyocytes Pubmed Central Canada , 2022 .

[136]  Gary L. Mantalas,et al.  Overview of High Throughput Sequencing Technologies to Elucidate Molecular Pathways in Cardiovascular Diseases , 2013, Circulation research.

[137]  Zachariah Gompert,et al.  Population genomics based on low coverage sequencing: how low should we go? , 2013, Molecular ecology.

[138]  Wolfgang Wagner,et al.  To Clone or Not to Clone? Induced Pluripotent Stem Cells Can Be Generated in Bulk Culture , 2013, PloS one.

[139]  M. Snyder,et al.  iPOP goes the world: integrated personalized Omics profiling and the road toward improved health care. , 2013, Chemistry & biology.

[140]  M. Kay,et al.  A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[141]  W. Frishman β-Adrenergic Blockade in Cardiovascular Disease , 2013, Journal of cardiovascular pharmacology and therapeutics.

[142]  Da-Zhi Wang,et al.  MicroRNA-22 Regulates Cardiac Hypertrophy and Remodeling in Response to Stress , 2013, Circulation research.

[143]  Donald M Bers,et al.  Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity , 2013, Circulation.

[144]  Philip Wong,et al.  Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. , 2013, European heart journal.

[145]  M. Pirmohamed,et al.  Expanding Role of Pharmacogenomics in the Management of Cardiovascular Disorders , 2013, American Journal of Cardiovascular Drugs.

[146]  P. Sham,et al.  Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome sequencing. , 2013, Human molecular genetics.

[147]  O. Cohen-Haguenauer,et al.  Send Orders of Reprints at Reprints@benthamscience.net Technological Overview of Ips Induction from Human Adult Somatic Cells , 2022 .

[148]  Hao Yan,et al.  DNA Gridiron Nanostructures Based on Four-Arm Junctions , 2013, Science.

[149]  Derrick J. Rossi,et al.  Reprogramming human fibroblasts to pluripotency using modified mRNA , 2013, Nature Protocols.

[150]  S. Yamanaka,et al.  An Efficient Nonviral Method to Generate Integration‐Free Human‐Induced Pluripotent Stem Cells from Cord Blood and Peripheral Blood Cells , 2013, Stem cells.

[151]  R. Pretorius,et al.  Reducing the risk of adverse drug events in older adults. , 2013, American family physician.

[152]  Shinya Yamanaka,et al.  Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[153]  Kevin Kim,et al.  A TALEN genome-editing system for generating human stem cell-based disease models. , 2013, Cell stem cell.

[154]  Carlos F. Barbas,et al.  A comprehensive approach to zinc-finger recombinase customization enables genomic targeting in human cells , 2013, Nucleic acids research.

[155]  H. McLeod,et al.  Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. , 2013, Pharmacogenomics.

[156]  Euan A Ashley,et al.  Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. , 2013, Cell stem cell.

[157]  M. Suematsu,et al.  Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. , 2013, Cell stem cell.

[158]  Ivan Rusyn,et al.  Multiparameter In Vitro Assessment of Compound Effects on Cardiomyocyte Physiology Using iPSC Cells , 2013, Journal of biomolecular screening.

[159]  Gordon Keller,et al.  Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics , 2013, The Journal of general physiology.

[160]  H. Calkins,et al.  Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs , 2012, Nature.

[161]  Divya Rajamohan,et al.  Current status of drug screening and disease modelling in human pluripotent stem cells , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.

[162]  遠山 周吾 Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes , 2013 .

[163]  P. Burridge,et al.  Generation of human iPSCs from human peripheral blood mononuclear cells using non-integrative Sendai virus in chemically defined conditions. , 2013, Methods in molecular biology.

[164]  H. R. Lu,et al.  Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes. , 2013, Stem cell research.

[165]  Hee Cheol Cho,et al.  Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18 , 2012, Nature Biotechnology.

[166]  Yi Zhang,et al.  Embryonic stem cell and induced pluripotent stem cell: an epigenetic perspective , 2012, Cell Research.

[167]  Tobias Schmidt,et al.  A ligation-independent cloning technique for high-throughput assembly of transcription activator–like effector genes , 2012, Nature Biotechnology.

[168]  P. Alagona,et al.  The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. , 2012, Journal of the American College of Cardiology.

[169]  Barry Merriman,et al.  Progress in Ion Torrent semiconductor chip based sequencing , 2012, Electrophoresis.

[170]  C. Siu,et al.  Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells , 2012, Aging.

[171]  Linzhao Cheng,et al.  Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression , 2012, Nature Protocols.

[172]  Siqun Xu,et al.  © The American Society of Gene & Cell Therapy original article The Extragenic Spacer Length Between the 5 ′ and 3 ′ Ends of the Transgene Expression Cassette Affects Transgene Silencing From Plasmid-based Vectors , 2012 .

[173]  W. Wong,et al.  Activation of Innate Immunity Is Required for Efficient Nuclear Reprogramming , 2012, Cell.

[174]  G. Lyons,et al.  Extracellular Matrix Promotes Highly Efficient Cardiac Differentiation of Human Pluripotent Stem Cells: The Matrix Sandwich Method , 2012, Circulation research.

[175]  A. Kuroiwa,et al.  Fibroblast growth factor 10 gene regulation in the second heart field by Tbx1, Nkx2-5, and Islet1 reveals a genetic switch for down-regulation in the myocardium , 2012, Proceedings of the National Academy of Sciences.

[176]  Carlos F. Barbas,et al.  Chimeric TALE recombinases with programmable DNA sequence specificity , 2012, Nucleic acids research.

[177]  Xi-rong Guo,et al.  Feeder-Free Derivation of Human Induced Pluripotent Stem Cells with Messenger RNA , 2012, Scientific Reports.

[178]  Michael Glikson,et al.  Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. , 2012, Journal of the American College of Cardiology.

[179]  Katriina Aalto-Setälä,et al.  Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Reveals Early and Delayed Afterdepolarizations , 2012, PloS one.

[180]  P. Elliott,et al.  Genetics and metabolic cardiomyopathies , 2012, Herz.

[181]  An integrated chip for the high-throughput synthesis of transcription activator-like effectors. , 2012, Angewandte Chemie.

[182]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[183]  Michael D. Schneider,et al.  Development of High Content Imaging Methods for Cell Death Detection in Human Pluripotent Stem Cell-Derived Cardiomyocytes , 2012, Journal of Cardiovascular Translational Research.

[184]  M. Kowalski,et al.  Controlling Embryonic Stem Cell Growth and Differentiation by Automation , 2012, Journal of biomolecular screening.

[185]  G. Salama,et al.  High-purity enrichment of functional cardiovascular cells from human iPS cells. , 2012, Cardiovascular research.

[186]  Anna M. McGeachy,et al.  The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments , 2012, Nature Protocols.

[187]  Ulf Leser,et al.  Data Management Challenges in Next Generation Sequencing , 2012, Datenbank-Spektrum.

[188]  H. Swerdlow,et al.  A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers , 2012, BMC Genomics.

[189]  Lin Liu,et al.  Comparison of Next-Generation Sequencing Systems , 2012, Journal of biomedicine & biotechnology.

[190]  D. Kass,et al.  Animal models of heart failure: a scientific statement from the American Heart Association. , 2012, Circulation research.

[191]  Sean P. Palecek,et al.  Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling , 2012, Proceedings of the National Academy of Sciences.

[192]  D. Rao,et al.  Whole-exome Sequencing and an iPSC-Derived Cardiomyocyte Model Provides a Powerful Platform for Gene Discovery in Left Ventricular Hypertrophy , 2012, Front. Gene..

[193]  C. Denning,et al.  In Vitro Uses of Human Pluripotent Stem Cell-Derived Cardiomyocytes , 2012, Journal of Cardiovascular Translational Research.

[194]  Ofer Binah,et al.  Cardiomyocytes derived from human pluripotent stem cells for drug screening. , 2012, Pharmacology & therapeutics.

[195]  M. Hayden,et al.  Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[196]  Euan A. Ashley,et al.  Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial Dilated Cardiomyopathy , 2012, Science Translational Medicine.

[197]  Natalia B. Ivanova,et al.  Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. , 2012, Cell stem cell.

[198]  Laura Iop,et al.  Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia , 2012, EMBO molecular medicine.

[199]  Ofer Binah,et al.  Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation , 2012, Journal of cellular and molecular medicine.

[200]  A. Franke,et al.  DNA methylome analysis using short bisulfite sequencing data , 2012, Nature Methods.

[201]  W. McKenna,et al.  Genetics of inherited cardiomyopathy. , 2012, European heart journal.

[202]  Gordon Keller,et al.  Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. , 2012, Cell stem cell.

[203]  A. Nagy,et al.  EMBRYONIC STEM CELLS / INDUCED PLURIPOTENT STEM CELLS Concise Review : Embryonic Stem Cells Versus Induced Pluripotent Stem Cells : The Game Is On , 2011 .

[204]  J. Bilić,et al.  Concise Review: Induced Pluripotent Stem Cells Versus Embryonic Stem Cells: Close Enough or Yet Too Far Apart? , 2012, Stem cells.

[205]  R. Thomas,et al.  Next generation sequencing in the clinical domain: clinical advantages, practical, and ethical challenges. , 2012, Advances in protein chemistry and structural biology.

[206]  Euan A Ashley,et al.  Performance comparison of whole-genome sequencing platforms , 2011, Nature Biotechnology.

[207]  Y. Chien,et al.  Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. , 2011, Human molecular genetics.

[208]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[209]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[210]  Barry J Maron,et al.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.

[211]  Azra Fatima,et al.  In vitro Modeling of Ryanodine Receptor 2 Dysfunction Using Human Induced Pluripotent Stem Cells , 2011, Cellular Physiology and Biochemistry.

[212]  Gordon Keller,et al.  SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells , 2011, Nature Biotechnology.

[213]  R. Russell,et al.  Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment , 2011, Current cardiology reviews.

[214]  M. Oshimura,et al.  Integration-Free iPS Cells Engineered Using Human Artificial Chromosome Vectors , 2011, PloS one.

[215]  Ssang-Goo Cho,et al.  The generation of iPS cells using non-viral magnetic nanoparticle based transfection. , 2011, Biomaterials.

[216]  Shinya Yamanaka,et al.  Efficient and Scalable Purification of Cardiomyocytes from Human Embryonic and Induced Pluripotent Stem Cells by VCAM1 Surface Expression , 2011, PloS one.

[217]  Naoki Nishishita,et al.  Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors , 2011, Proceedings of the National Academy of Sciences.

[218]  Tina Hernandez-Boussard,et al.  Doxorubicin pathways: pharmacodynamics and adverse effects , 2011, Pharmacogenetics and genomics.

[219]  N. Terada,et al.  Induced pluripotent stem cells as a next-generation biomedical interface , 2011, Laboratory Investigation.

[220]  P. Oliveira,et al.  Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. , 2011, Current pharmaceutical design.

[221]  H. Steven Wiley,et al.  Characterization and improvement of RNA-Seq precision in quantitative transcript expression profiling , 2011, Bioinform..

[222]  Mitsugu Sekimoto,et al.  Reprogramming of mouse and human cells to pluripotency using mature microRNAs. , 2011, Cell stem cell.

[223]  E. Quigley,et al.  Cisapride: What can we learn from the rise and fall of a prokinetic? , 2011, Journal of digestive diseases.

[224]  A. Y. Lu,et al.  Pharmacogenetics, Pharmacogenomics, and Individualized Medicine , 2011, Pharmacological Reviews.

[225]  William Sun,et al.  Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells. , 2011, Cardiovascular research.

[226]  Xuan Yuan,et al.  A Universal System for Highly Efficient Cardiac Differentiation of Human Induced Pluripotent Stem Cells That Eliminates Interline Variability , 2011, PloS one.

[227]  Stéphanie Boué,et al.  Methods for making induced pluripotent stem cells: reprogramming à la carte , 2011, Nature Reviews Genetics.

[228]  Jonathan A. Bernstein,et al.  Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome , 2011, Nature.

[229]  Lior Gepstein,et al.  Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.

[230]  Riitta Lahesmaa,et al.  Copy number variation and selection during reprogramming to pluripotency , 2011, Nature.

[231]  Divya Rajamohan,et al.  Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation , 2011, European heart journal.

[232]  Hanns Lochmüller,et al.  Two new protocols to enhance the production and isolation of human induced pluripotent stem cell lines. , 2011, Stem cell research.

[233]  Junying Yu,et al.  Efficient Feeder-Free Episomal Reprogramming with Small Molecules , 2011, PloS one.

[234]  Elaine R. Mardis,et al.  A decade’s perspective on DNA sequencing technology , 2011, Nature.

[235]  Gordon Keller,et al.  Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. , 2011, Cell stem cell.

[236]  Tomohide Takaya Identification of p300-targeted acetylated residues in GATA4 during hypertrophic responses in cardiac myocytes , 2011 .

[237]  Peter G Schultz,et al.  Stepwise chemically induced cardiomyocyte specification of human embryonic stem cells. , 2011, Angewandte Chemie.

[238]  Weiqi Zhang,et al.  Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules , 2011, Cell Research.

[239]  Shinya Yamanaka,et al.  Induced Pluripotent Stem Cells , 2011, SpringerBriefs in Stem Cells.

[240]  Michael T Longaker,et al.  Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors , 2011, Nature Protocols.

[241]  Russell M Gordley,et al.  Structure-guided reprogramming of serine recombinase DNA sequence specificity , 2010, Proceedings of the National Academy of Sciences.

[242]  Alexander Meissner,et al.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.

[243]  K. Hochedlinger,et al.  Induced pluripotency: history, mechanisms, and applications. , 2010, Genes & development.

[244]  Karl-Ludwig Laugwitz,et al.  Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, New England Journal of Medicine.

[245]  Johnf . Thompson,et al.  Single Molecule Sequencing with a HeliScope Genetic Analysis System , 2010, Current protocols in molecular biology.

[246]  Wei-Zhong Zhu,et al.  Neuregulin/ErbB Signaling Regulates Cardiac Subtype Specification in Differentiating Human Embryonic Stem Cells , 2010, Circulation research.

[247]  M. Snyder,et al.  ChIP‐Seq: A Method for Global Identification of Regulatory Elements in the Genome , 2010, Current protocols in molecular biology.

[248]  Olga K Afanasiev,et al.  Endogenous Wnt/β-Catenin Signaling Is Required for Cardiac Differentiation in Human Embryonic Stem Cells , 2010, PloS one.

[249]  B. Tomlinson,et al.  ABCG2 Polymorphism Is Associated With the Low‐Density Lipoprotein Cholesterol Response to Rosuvastatin , 2010, Clinical pharmacology and therapeutics.

[250]  P. Itsykson,et al.  Derivation, propagation and controlled differentiation of human embryonic stem cells in suspension , 2010, Nature Biotechnology.

[251]  Lei Yang,et al.  Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome , 2010, Nature.

[252]  Deepak M. Gupta,et al.  A nonviral minicircle vector for deriving human iPS cells , 2010, Nature Methods.

[253]  J. Monshouwer-Kloots,et al.  Identification of cell surface proteins for antibody-based selection of human embryonic stem cell-derived cardiomyocytes. , 2010, Journal of proteome research.

[254]  S. Rahman,et al.  Prevalence and natural history of heart disease in adults with primary mitochondrial respiratory chain disease , 2010, European journal of heart failure.

[255]  Jin-Soo Kim,et al.  Genome editing with modularly assembled zinc-finger nucleases , 2010, Nature Methods.

[256]  E. Sasaki,et al.  Nongenetic method for purifying stem cell–derived cardiomyocytes , 2010, Nature Methods.

[257]  Norman Honbo,et al.  Doxorubicin Cardiomyopathy , 2009, Cardiology.

[258]  Wenbo Zhou,et al.  Adenoviral Gene Delivery Can Reprogram Human Fibroblasts to Induced Pluripotent Stem Cells , 2009, Stem cells.

[259]  Robert Passier,et al.  Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. , 2009, Trends in pharmacological sciences.

[260]  M. Hasegawa,et al.  Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome , 2009, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[261]  S. Yamanaka,et al.  The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. , 2009, Biochemical and biophysical research communications.

[262]  Jian-Fu Chen,et al.  MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. , 2009, The Journal of clinical investigation.

[263]  Y. Kaneda,et al.  A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf–Hirschhorn syndrome , 2009, Nature.

[264]  Robert Lanza,et al.  Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. , 2009, Cell stem cell.

[265]  N. Lévêque,et al.  Viral causes of human myocarditis. , 2009, Archives of cardiovascular diseases.

[266]  R. Hajjar,et al.  Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates , 2009, Expert opinion on drug metabolism & toxicology.

[267]  Thomas J. Hardcastle,et al.  Chromosomal instability determines taxane response , 2009, Proceedings of the National Academy of Sciences.

[268]  R. Stewart,et al.  Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.

[269]  Dong Wook Han,et al.  Generation of induced pluripotent stem cells using recombinant proteins. , 2009, Cell stem cell.

[270]  David J. Williams,et al.  Automated, scalable culture of human embryonic stem cells in feeder‐free conditions , 2009, Biotechnology and bioengineering.

[271]  T. Cantz,et al.  Induced pluripotent stem cells generated without viral integration , 2009, Hepatology.

[272]  K. Woltjen,et al.  Virus free induction of pluripotency and subsequent excision of reprogramming factors , 2009, Nature.

[273]  Rudolf Jaenisch,et al.  Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors , 2009, Cell.

[274]  D. Rossi,et al.  Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 , 2009, Leukemia.

[275]  N. Shanks,et al.  Are animal models predictive for humans? , 2009, Philosophy, ethics, and humanities in medicine : PEHM.

[276]  N. Avent,et al.  Toxicity testing: the search for an in vitro alternative to animal testing , 2009, British journal of biomedical science.

[277]  Z. Storchová,et al.  The consequences of tetraploidy and aneuploidy , 2008, Journal of Cell Science.

[278]  Paul S Price,et al.  Characterizing interspecies uncertainty using data from studies of anti-neoplastic agents in animals and humans. , 2008, Toxicology and applied pharmacology.

[279]  Wenjun Guo,et al.  Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2 , 2008, Nature Biotechnology.

[280]  George Q. Daley,et al.  Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.

[281]  Hynek Wichterle,et al.  Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons , 2008, Science.

[282]  Michael Kyba,et al.  Mesp1 acts as a master regulator of multipotent cardiovascular progenitor specification. , 2008, Cell stem cell.

[283]  Z. Herceg,et al.  Epigenetic interplay between histone modifications and DNA methylation in gene silencing. , 2008, Mutation research.

[284]  Eric D. Adler,et al.  Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population , 2008, Nature.

[285]  T. Kita,et al.  Identification of p300-targeted Acetylated Residues in GATA4 during Hypertrophic Responses in Cardiac Myocytes*♦ , 2008, Journal of Biological Chemistry.

[286]  Jim Stalker,et al.  A Novel CpG Island Set Identifies Tissue-Specific Methylation at Developmental Gene Loci , 2008, PLoS biology.

[287]  Wolf-Dietrich Heyer,et al.  Homologous recombination in DNA repair and DNA damage tolerance , 2008, Cell Research.

[288]  Takashi Aoi,et al.  Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts , 2008, Nature Biotechnology.

[289]  Masafumi Okumura,et al.  Heterogeneity of pluripotent marker gene expression in colonies generated in human iPS cell induction culture. , 2008, Stem cell research.

[290]  Shulan Tian,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[291]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[292]  Lila R Collins,et al.  Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts , 2007, Nature Biotechnology.

[293]  John M. Haynes,et al.  Embryonic stem cells as a source of models for drug discovery , 2007, Nature Reviews Drug Discovery.

[294]  D. Loebel,et al.  Gene function in mouse embryogenesis: get set for gastrulation , 2007, Nature Reviews Genetics.

[295]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[296]  Barry J Maron,et al.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.

[297]  T. Self,et al.  Common culture conditions for maintenance and cardiomyocyte differentiation of the human embryonic stem cell lines, BG01 and HUES-7. , 2006, The International journal of developmental biology.

[298]  Robert Zweigerdt,et al.  Differentiation and lineage selection of mouse embryonic stem cells in a stirred bench scale bioreactor with automated process control. , 2005, Biotechnology and bioengineering.

[299]  M. Pfreundschuh,et al.  NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity , 2005, Circulation.

[300]  Younghee Lee,et al.  Basic fibroblast growth factor activates ERK and induces c-fos in human embryonic stem cell line MizhES1. , 2005, Stem cells and development.

[301]  C. Macrae,et al.  Animal models for arrhythmias. , 2005, Cardiovascular research.

[302]  J. Itskovitz‐Eldor,et al.  No Evidence for Infection of Human Embryonic Stem Cells by Feeder Cell–Derived Murine Leukemia Viruses , 2005, Stem cells.

[303]  John McAnally,et al.  BOP, a regulator of right ventricular heart development, is a direct transcriptional target of MEF2C in the developing heart , 2005, Development.

[304]  A. Marian,et al.  Pharmacogenetic study of statin therapy and cholesterol reduction. , 2005, Current atherosclerosis reports.

[305]  M. Mercola,et al.  Heart induction by Wnt antagonists depends on the homeodomain transcription factor Hex. , 2005, Genes & development.

[306]  T. Meyer,et al.  QT-screen: high-throughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes. , 2004, Assay and drug development technologies.

[307]  D. Constam,et al.  A gene network establishing polarity in the early mouse embryo. , 2004, Seminars in cell & developmental biology.

[308]  E. Corwin The Concept of Epigenetics and Its Role in the Development of Cardiovascular Disease: Commentary on “New and Emerging Theories of Cardiovascular Disease” , 2004, Biological research for nursing.

[309]  Steffen Bauer,et al.  Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.

[310]  M. Kay,et al.  Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[311]  R. Harvey,et al.  Molecular pathways in myocardial development: a stem cell perspective. , 2003, Cardiovascular research.

[312]  G. Dorn,et al.  Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. , 2003, The Journal of clinical investigation.

[313]  A. Bird,et al.  Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals , 2003, Nature Genetics.

[314]  Chunhui Xu,et al.  Characterization and Enrichment of Cardiomyocytes Derived From Human Embryonic Stem Cells , 2002, Circulation research.

[315]  I. Komuro,et al.  The Polycomb-group gene Rae28 sustains Nkx2.5/Csx expression and is essential for cardiac morphogenesis. , 2002, The Journal of clinical investigation.

[316]  J. Schmitt,et al.  A Murine Model of Holt-Oram Syndrome Defines Roles of the T-Box Transcription Factor Tbx5 in Cardiogenesis and Disease , 2001, Cell.

[317]  Ryozo Nagai,et al.  Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation , 2001, Nature Genetics.

[318]  E. Kieff,et al.  Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[319]  D M Roden,et al.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[320]  D. Applegarth,et al.  Incidence of Inborn Errors of Metabolism in British Columbia, 1969–1996 , 2000, Pediatrics.

[321]  J. Thomson,et al.  Embryonic stem cell lines derived from human blastocysts. , 1998, Science.

[322]  G.E. Moore,et al.  Cramming More Components Onto Integrated Circuits , 1998, Proceedings of the IEEE.

[323]  D R Illingworth,et al.  The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. , 1997, The American journal of cardiology.

[324]  R. Buller,et al.  Vaccinia Virus B18R Gene Encodes a Type I Interferon-binding Protein That Blocks Interferon α Transmembrane Signaling (*) , 1995, The Journal of Biological Chemistry.

[325]  F. Schoen,et al.  Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. , 1987, Circulation.

[326]  L. Liu,et al.  Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[327]  L. Liu,et al.  Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[328]  J. Gurdon,et al.  Adult frogs derived from the nuclei of single somatic cells. , 1962, Developmental biology.